Update in Glomerular Disease 2024 - 13th Annual (Enduring)
Update in Glomerular Disease 2024 - 13th Annual (Enduring)
8.0 ACCME Credits, Video On-Demand/Enduring Program
August 02, 2024
8:20 AM - 5:00 PM (ET)

Program Overview
VIDEO ON-DEMAND/ENDURING PROGRAM AVAILABLE ONLINE THRU AUGUST 2, 2024

Program covers recent advances in the diagnosis and management of glomerular disease in a one-day course.

Brought to you from the:





Learning Objectives

Explore the latest treatment guidelines for Lupus nephritis, IgA nephropathy, ANCA vasculitis, and monoclonal gammopathy. They will understand the importance of individualized treatment plans based on disease severity, patient characteristics, and comorbidities.

 

Target therapies, including complement inhibitors, B cell targeted therapies, endothelin-angiotensin system modulators, and plasma cell therapies, are promising treatment options for glomerular diseases. Learners will understand these therapies' mechanisms of action, indications, and potential side effects.

 

Discuss insights into the role of SGLT2 inhibitors in managing diabetic nephropathy. The course will cover the mechanisms through which these drugs improve renal outcomes in diabetic patients and explore the evidence supporting their use in reducing proteinuria and preserving renal function.

 

Identify potential treatment-related adverse events associated with the targeted therapies discussed in the course. They will learn to monitor patients for these adverse events and develop strategies to manage them effectively while ensuring optimal patient outcomes.

 

Discuss case studies and real-world scenarios to illustrate the application of targeted therapies in managing glomerular diseases. Learners will be encouraged to engage in interactive discussions to analyze and develop appropriate treatment plans based on each case.


Video Access

All registrants will be sent a link to videos to watch in their own time.

Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Columbia University. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Amedco Joint Accreditation #4008163.


Physicians (ACCME) Credit Designation Statement
Amedco LLC designates this live virtual activity for a maximum of 8.0
AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
PAs may claim a maximum of 8
.0 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Nurse Practitioners
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit. Maximum of 8.0 hours.


Agenda
Click to View
Course Directors
Associate Professor of Medicine, Division of Nephrology
Columbia University
Professor of Medicine, Clinical Chief, Division of Nephrology
Columbia University
Associate Professor of Medicine, Division of Nephrology
Columbia University

No records found.